Compass Therapeutics (NASDAQ:CMPX) Stock Price Down 1.8% - Should You Sell?

Key Points

• Compass Therapeutics shares fell 1.8% to approximately $0.75, with trading volume 60% below its average. The stock remains well below its 50-day and 200-day moving averages of $1.59 and $3.32, respectively.
• Analyst sentiment is mixed but leans positive: MarketBeat reports a “Moderate Buy” consensus and an average price target of $10.25, although recent ratings ranged from “Strong Sell” to “Overweight” and some analysts lowered their targets.
• The clinical-stage biotechnology company reported a quarterly loss of $0.13 per share, missing estimates by $0.02, while institutional investors own 68.43% of the stock. Compass is developing antibody-based cancer therapies, including its lead candidate CTX-471.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was down 1.8% on Monday. The stock traded as low as $0.7409 and last traded at $0.7472. 2,214,680 shares were traded during trading, a decline of 60% from the average daily volume of 5,487,066 shares. The stock had previously closed at $0.7610.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on CMPX shares. Citizens Jmp lowered their price objective on shares of Compass Therapeutics to $4.00 and set a "market outperform" rating on the stock in a research report on Wednesday, September 23rd. Citigroup restated a "market outperform" rating on shares of Compass Therapeutics in a research report on Wednesday, September 23rd. Wall Street Zen cut shares of Compass Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 8th. Lifesci Capital cut shares of Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 22nd. Finally, Piper Sandler raised their price objective on shares of Compass Therapeutics from $4.00 to $6.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $10.25.

Compass Therapeutics Stock Performance

The business has a fifty day simple moving average of $1.59 and a 200 day simple moving average of $3.32. The stock has a market cap of $134.56 million, a price-to-earnings ratio of -1.87 and a beta of 1.02.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, equities research analysts anticipate that Compass Therapeutics, Inc. will post -0.47 EPS for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Compass Therapeutics in the 2nd quarter worth about $24,707,000. Palo Alto Investors LP acquired a new stake in Compass Therapeutics during the 2nd quarter worth approximately $12,771,670. Squarepoint Ops LLC increased its position in Compass Therapeutics by 1,906.9% during the 2nd quarter. Squarepoint Ops LLC now owns 1,007,507 shares of the company's stock worth $2,206,000 after purchasing an additional 957,305 shares in the last quarter. Bank of America Corp DE increased its position in Compass Therapeutics by 224.9% during the 1st quarter. Bank of America Corp DE now owns 865,613 shares of the company's stock worth $4,579,000 after purchasing an additional 599,179 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Compass Therapeutics in the second quarter valued at approximately $1,147,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company's research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer.

Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.